...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: I'll believe
For the same reason I believe in a deal sooner than later as almost all Pharma's are flush with cash now & can grab it much cheaper at this moment in time + given the safety record & success thus far I believe that's a risk they may be willing to take on now? 
 
Does this make a little sense or am I way off base?
Sooner would be good I can only guess.
 

 

Share
New Message
Please login to post a reply